Research graph
References from Targeted protein degradation in mammalian cells: A promising avenue toward future. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1038/nrmicro3239
10.1038/nrmicro3239 · External reference
10.1002/biot.201400642
10.1002/biot.201400642 · External reference
10.1021/ja039025z
10.1021/ja039025z · External reference
10.1126/science.2660260
10.1126/science.2660260 · External reference
10.1126/science.1258096
10.1126/science.1258096 · External reference
Springer International Publishing
2015 · External reference
CRISPR/Cas9 for Cancer Therapy: Hopes and Challenges
10.3390/biomedicines6040105 · 2018 · External reference
10.1038/35078107
10.1038/35078107 · External reference
10.1038/s41580-018-0024-z
10.1038/s41580-018-0024-z · External reference
10.1016/j.cell.2017.10.033
10.1016/j.cell.2017.10.033 · External reference
10.1038/s41594-020-0438-0
10.1038/s41594-020-0438-0 · External reference
Sorting, recognition and activation of the misfolded protein degradation pathways through macroautophagy and the proteasome
10.4161/auto.5190 · 2008 · External reference
10.1016/j.molcel.2004.12.021
10.1016/j.molcel.2004.12.021 · External reference
10.1016/0955-0674(95)80031-x
10.1016/0955-0674(95)80031-x · External reference
10.1038/nature02263
10.1038/nature02263 · External reference
10.1093/hmg/ddr048
10.1093/hmg/ddr048 · External reference
10.1016/j.bbrc.2014.05.078
10.1016/j.bbrc.2014.05.078 · External reference
Cracking the Ubiquitin Code: The Ubiquitin Toolbox
10.21775/cimb.037.001 · 2020 · External reference
E3 ubiquitin ligases: styles, structures and functions
10.1186/s43556-021-00043-2 · 2021 · External reference
10.1038/ncb1402
10.1038/ncb1402 · External reference
10.1016/j.cell.2016.03.003
10.1016/j.cell.2016.03.003 · External reference
10.1371/journal.pone.0022356
10.1371/journal.pone.0022356 · External reference
10.1042/bj20140006
10.1042/bj20140006 · External reference
10.15252/embr.201642641
10.15252/embr.201642641 · External reference
10.1016/j.tips.2020.04.005
10.1016/j.tips.2020.04.005 · External reference
10.1016/s1097-2765(00)00074-5
10.1016/s1097-2765(00)00074-5 · External reference
10.1016/j.bbrc.2003.12.035
10.1016/j.bbrc.2003.12.035 · External reference
10.1073/pnas.2133261100
10.1073/pnas.2133261100 · External reference
10.1186/1471-2199-4-10
10.1186/1471-2199-4-10 · External reference
10.1158/0008-5472.can-03-3906
10.1158/0008-5472.can-03-3906 · External reference
10.1073/pnas.082240999
10.1073/pnas.082240999 · External reference
10.1007/s12013-013-9621-9
10.1007/s12013-013-9621-9 · External reference
Synthetic biology approaches for targeted protein degradation
2019 · External reference
A modular degron library for synthetic circuits in mammalian cells
10.1038/s41467-019-09974-5 · 2019 · External reference
Targeted protein degradation: expanding the toolbox
2019 · External reference
10.1126/science.1065203
10.1126/science.1065203 · External reference
10.1038/35107009
10.1038/35107009 · External reference
Structure of a beta-TrCP1-Skp1-beta-catenin complex: Destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase
2003 · External reference
Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line.
10.1038/35095076 · 2001 · External reference
10.1038/nature05731
10.1038/nature05731 · External reference
10.1016/j.cell.2006.07.025
10.1016/j.cell.2006.07.025 · External reference
10.1016/j.ymthe.2020.06.004
10.1016/j.ymthe.2020.06.004 · External reference
Efficient protein depletion by genetically controlled deprotection of a dormant N-degron
10.1038/msb.2009.25 · 2009 · External reference
deGradFP: A System to Knockdown GFP-Tagged Proteins [J]
10.1007/978-1-4939-6371-3_9 · 2016 · External reference
10.1038/nchembio.1869
10.1038/nchembio.1869 · External reference
10.1038/nmeth.1401
10.1038/nmeth.1401 · External reference
The auxin-inducible degradation (AID) system enables versatile conditional protein depletion in C. elegans
2015 · External reference
10.1080/19336934.2016.1168552
10.1080/19336934.2016.1168552 · External reference
10.1016/j.molcel.2020.01.010
10.1016/j.molcel.2020.01.010 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.1021/cb400755b
10.1021/cb400755b · External reference
10.1021/cb800025k
10.1021/cb800025k · External reference
10.1038/s41589-018-0021-8
10.1038/s41589-018-0021-8 · External reference
10.1038/nature21688
10.1038/nature21688 · External reference
10.1016/j.ccell.2018.08.005
10.1016/j.ccell.2018.08.005 · External reference
10.1016/j.cell.2017.11.008
10.1016/j.cell.2017.11.008 · External reference
10.1073/pnas.1818109116
10.1073/pnas.1818109116 · External reference
10.1021/acschembio.6b01068
10.1021/acschembio.6b01068 · External reference
The PROTAC technology in drug development
10.1002/cbf.3369 · 2019 · External reference
10.1073/pnas.141230798
10.1073/pnas.141230798 · External reference
10.1074/mcp.t300009-mcp200
10.1074/mcp.t300009-mcp200 · External reference
10.1126/science.1092472
10.1126/science.1092472 · External reference
10.1016/j.bmcl.2008.07.114
10.1016/j.bmcl.2008.07.114 · External reference
Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC)
10.1200/jco.2022.40.6_suppl.017 · 2022 · External reference
ARV-471, an estrogen receptor (ER) PROTACdegrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study
10.1200/jco.2022.40.16_suppl.tps1120 · 2022 · External reference
Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MM
10.1158/1538-7445.am2022-ct186 · 2022 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
P686: a phase 1 first in-human study of BGB-16673, a Bruton tyrosine kinase protein degrader, in patients (PTS) with B-cell malignancies (trial in progress)
10.1097/01.hs9.0000845628.43637.11 · 2022 · External reference
Unresolved reference
External reference
Degradation of Bcl-xL by DT2216 is lethal to T-cell acute lymphoblastic leukemia
10.1158/1538-7445.am2022-5654 · 2022 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.1158/1538-7445.am2020-6367
10.1158/1538-7445.am2020-6367 · External reference
10.1158/1538-7445.am2020-5327
10.1158/1538-7445.am2020-5327 · External reference
Phase 1 study of KT-333, a targeted protein degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia, and solid tumors
10.1200/jco.2022.40.16_suppl.tps3171 · 2022 · External reference
Phase 1 study of KT-413, a targeted protein degrader, in adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma
10.1200/jco.2022.40.16_suppl.tps3170 · 2022 · External reference
Unresolved reference
External reference
A first-in-human phase 1 trial of NX-2127, a first-in-class oral BTK degrader with IMiD-like activity, in patients with relapsed and refractory B-cell malignancies
10.1200/jco.2022.40.16_suppl.tps7581 · 2022 · External reference
P650: a first-in-human phase 1 trial of NX-5948, an oral BTK degrader, in patients with relapsed and refractory B-cell malignancies
10.1097/01.hs9.0000845484.57038.64 · 2022 · External reference
The discovery and characterization of CFT8634: A potent and selective degrader of BRD9 for the treatment of SMARCB1-perturbed cancers
10.1158/1538-7445.am2022-nd09 · 2022 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
10.1126/science.aao5902
10.1126/science.aao5902 · External reference
10.1038/s41589-020-0469-1
10.1038/s41589-020-0469-1 · External reference
10.1016/j.devcel.2014.09.008
10.1016/j.devcel.2014.09.008 · External reference
10.1126/science.1702904
10.1126/science.1702904 · External reference
10.1016/j.ddtec.2019.02.004
10.1016/j.ddtec.2019.02.004 · External reference
Intracellular antibody receptor TRIM21 prevents fatal viral infection
10.1073/pnas.1301918110 · 2013 · External reference
10.1073/pnas.0800159105
10.1073/pnas.0800159105 · External reference
10.1016/j.pharmthera.2017.02.027
10.1016/j.pharmthera.2017.02.027 · External reference
Degradation of endogenous proteins and generation of a null-like phenotype in zebrafish using Trim-Away technology
10.1186/s13059-019-1624-4 · 2019 · External reference
Unresolved reference
2020 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Nanogel-Facilitated Protein Intracellular Specific Degradation through Trim-Away
10.1002/adfm.202010556 · 2021 · External reference
A Promising Intracellular Protein-Degradation Strategy: TRIMbody-Away Technique Based on Nanobody Fragment
10.3390/biom11101512 · 2021 · External reference
10.1038/s41594-021-00560-2
10.1038/s41594-021-00560-2 · External reference
Elevated RIF1 participates in the epigenetic abnormalities of zygotes by regulating histone modifications on MuERV-L in obese mice
10.1186/s10020-022-00446-z · 2022 · External reference
TRF1 Depletion Reveals Mutual Regulation Between Telomeres, Kinetochores, and Inner Centromeres in Mouse Oocytes
2021 · External reference
Intracellular delivery of anti-BCR/ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells
10.1186/s13045-021-01150-x · 2021 · External reference
The COP9 signalosome subunit 3 is necessary for early embryo survival by way of a stable protein deposit in mouse oocytes
10.1093/molehr/gaab048 · 2021 · External reference
Intracellular targeting of STIP1 inhibits human cancer cell line growth
10.21037/tcr-20-3333 · 2021 · External reference
10.15252/embj.2020106812
10.15252/embj.2020106812 · External reference
10.1038/s41467-021-21020-x
10.1038/s41467-021-21020-x · External reference
Targeted intracellular degradation of SARS-CoV-2 via computationally optimized peptide fusions
10.1038/s42003-020-01470-7 · 2020 · External reference
Monoclonal full-length antibody against TAR DNA binding protein 43 reduces related proteinopathy in neurons
10.1172/jci.insight.140420 · 2020 · External reference
G4C2 Repeat RNA Initiates a POM121-Mediated Reduction in Specific Nucleoporins in C9orf72 ALS/FTD
10.1016/j.neuron.2020.06.027 · 2020 · External reference
10.1126/sciadv.aaz5004
10.1126/sciadv.aaz5004 · External reference
Characterization of zygotic genome activation-dependent maternal mRNA clearance in mouse
2019 · External reference
Ran GTP and importin β regulate meiosis I spindle assembly and function in mouse oocytes
2019 · External reference
Unresolved reference
External reference
A framework for TRIM21-mediated protein depletion in early mouse embryos: Recapitulation of Tead4 null phenotype over three days
10.1186/s12864-019-6106-2 · 2019 · External reference
Loss of CENPF leads to developmental failure in mouse embryos
2019 · External reference
SNAP23 is required for constitutive and regulated exocytosis in mouse oocytes
10.1093/biolre/ioz106 · 2019 · External reference
Molecular Strategies to Target Protein Aggregation in Huntington’s Disease
10.3389/fmolb.2021.769184 · 2021 · External reference
10.1126/science.1260419
10.1126/science.1260419 · External reference
10.1038/s41586-020-2545-9
10.1038/s41586-020-2545-9 · External reference
10.1016/j.ymgme.2012.07.012
10.1016/j.ymgme.2012.07.012 · External reference
The asialoglycoprotein receptor clears glycoconjugates terminating with sialic acidα2,6GalNAc
10.1073/pnas.0508537102 · 2005 · External reference
Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate
10.1016/j.ymthe.2016.10.019 · 2017 · External reference
10.1038/s41589-021-00770-1
10.1038/s41589-021-00770-1 · External reference
10.1038/s41589-020-0622-x
10.1038/s41589-020-0622-x · External reference
Microautophagy – distinct molecular mechanisms handle cargoes of many sizes
10.1242/jcs.246322 · 2020 · External reference
10.1021/acs.jmedchem.0c01689
10.1021/acs.jmedchem.0c01689 · External reference
10.1210/er.2016-1103
10.1210/er.2016-1103 · External reference
10.1038/nn.3637
10.1038/nn.3637 · External reference
The Peptide-Directed Lysosomal Degradation of CDK5 Exerts Therapeutic Effects against Stroke
10.14336/ad.2018.1225 · 2019 · External reference
10.1038/s41589-018-0161-x
10.1038/s41589-018-0161-x · External reference
10.1016/j.molcel.2019.09.009
10.1016/j.molcel.2019.09.009 · External reference
10.1039/d1cc04661f
10.1039/d1cc04661f · External reference
10.1038/s41586-019-1722-1
10.1038/s41586-019-1722-1 · External reference
10.1038/s41582-020-0389-4
10.1038/s41582-020-0389-4 · External reference
10.1038/s41422-021-00532-7
10.1038/s41422-021-00532-7 · External reference
10.1038/s41467-022-28520-4
10.1038/s41467-022-28520-4 · External reference
10.1038/sj.cr.7310053
10.1038/sj.cr.7310053 · External reference
10.1016/j.bbrc.2016.01.158
10.1016/j.bbrc.2016.01.158 · External reference
10.1016/j.crchbi.2022.100020
10.1016/j.crchbi.2022.100020 · External reference
sdAb-DB: The Single Domain Antibody Database
10.1021/acssynbio.8b00407 · 2018 · External reference
10.1182/blood.2020008676
10.1182/blood.2020008676 · External reference
